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Abstract Cyclin A is a pivotal regulatory protein which, in 
mammalian cells, is involved in the S phase of the cell cycle. 
Transcription of the human cyclin A gene is cell cycle regulated 
through tight control of its promoter. We have previously shown 
that the ATFlCREB site, present in the cyclin A promoter, 
mediates transcriptional regulation by CAMP responsive element 
binding proteins. The main goal of the present study was to 
investigate whether this site is involved in transcriptional 
regulation of the gene. We have constructed stable NIH-3T3 
cell lines that express the luciferase reporter gene under the 
control of normal or mutated versions of the cyclin A promoter. 
We show that the ATFKREB is required to achieve maximal 
levels of transcription from the cyclin A promoter starting in late 
Gl. We also show that down-regulation of the cyclin A promoter 
by ~53 does not implicate a direct binding of ~53 to its cognate 
consensus sequence but occurs probably by interference with 
trans-activating factors. This result suggests that ~53 can 
interfere with transcription of the cyclin A gene, in the absence 
of a TATA sequence in the promoter. 
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1. Introduction 
The cyclins are a group of proteins periodically synthesized 
and degraded during the cell cycle. This enables them to acti- 
vate, at the appropriate time, the cyclin-dependent kinases 
(cdks), whose activity is needed to drive cells through the 
cell-cycle (for recent reviews, see [l-3]). 
Mammalian cyclin A binds and activates cdk2 in S phase 
and cdkl (cdc2) in G2 and M phase [4-61. In vertebrates, 
following synthesis in late Gl, cyclin A accumulates in the 
nucleus [7], a process which appears to depend on its associa- 
tion with cdk2 [8]. The cyclin A/cdk2 kinase activity is present 
during S phase and is necessary for S phase entry; direct 
inhibition of S phase entry was observed in tissue culture cells 
following microinjection of antisense cDNA or anti-cyclin A 
antibodies [9-111. The same phenomenon occurred after mi- 
croinjection of antibodies directed against cdk2 [12]. Localiza- 
tion of cyclin A at the replication sites in vivo [13,14], the 
interaction of the cyclin A/cdk 2 kinase with the proliferating 
cell nuclear antigen (PCNA) [15] and the phosphorylation of 
the DNA replication factor RPA by cyclin A/cdk2 kinase 
[ 16,171 further support the hypothesis that cyclin A is involved 
in DNA replication. In addition, deregulated expression of 
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cyclin A can disturb the normal regulation of the Gl-to-S 
transition [18,19]. 
The cyclin A gene contains eight exons spanning 8 kb of 
DNA with a TATA-less promoter and multiple transcrip- 
tional start sites have been identified by Sl nuclease protection 
analysis [20]. A number of different studies have examined the 
mechanisms controlling the synthesis of cyclin A. Basal tran- 
scription of the cyclin A gene appears to require TAFn 250, 
the largest subunit of TFIID [21]. Another study has demon- 
strated that both cyclin A mRNA levels and E2F activity are 
increased in cells overexpressing c-myc, suggesting that E2F 
may be involved in the positive regulation of cyclin A expres- 
sion [22]. A variant E2F site was recently shown to mediate 
this positive regulation at S phase entry [23]. Cell cycle 
dependent elements have also been recently identified. Tran- 
scriptional repression of the cyclin A gene during the GO and 
Gl phases is mediated by two distinct elements: a cell cycle- 
dependent element (CDE) and a cell cycle gene homology 
region (CHR) [24]. The CDE-mediated repression is also the 
principle underlying the periodic transcription of the human 
cdc25C and cdc2 genes. However, identification of positive 
and negative cis-acting sequences implicated in the promoter 
regulation during the cell cycle is still incomplete. 
The main goal of the present study was to investigate 
whether the ATF/CREB and p53 sites might be involved in 
the periodic transcription of the cyclin A gene. We have re- 
cently shown that the ATFlCREB site located in the cyclin A 
promoter shows a cell cycle-regulated response to stimulation 
by the CAMP signal transduction pathway [25]. Moreover, the 
same site has been also implicated in cyclin A-promoter 
down-regulation in contact-inhibited endothelial cells [26] 
and in Chinese hamster lung fibroblasts upon treatment with 
TGF-fi [27]. Altogether, these results identified the ATFI 
CREB site as a central element of the cyclin A promoter. 
Negative transcriptional regulation of the cyclin A gene by 
p53 was also recently reported in human and rat cells, but the 
significance of this regulation during the cell cycle was unclear 
[28]. It has been demonstrated that wild type p53 is able to 
down-regulate transcription of promoters containing a TATA 
box element [29,30]. This repression is believed to be due to 
the capacity of p53 to interfere with the assembly of the tran- 
scriptional complex on the TATA site. However, ~53 is a 
transactivating protein that is able to activate transcription 
of genes containing a specific p53 DNA binding element 
such as WAF/CIPl, mdm-2, GADD45, Bax, cyclin G or 
IGFBP3 [3 l-361. 
In this study, we show that the ATFICREB is required to 
achieve maximal levels of transcription from the cyclin A 
promoter starting in late Gl. In contrast, down-regulation 
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of the cyclin A promoter by ~53 did not involve a direct 
binding of p53 to its cognate consensus sequence but occurred 
probably through interference with trans-activating factors. 
2. Materials and methods 
2.1. Plasmid construction 
The cyclin A promoter region (a 1292 bp Bgfll-Smal fragment) was 
cloned in a luciferase reporter plasmid [37] to generate the pWT-LUC 
plasmid [20]. pdelATF/CREB-LUC, pdelp53-LUC were obtained by 
site-directed mutagenesis of the ATFICREB, ~53 sequences of pWT- 
LUC (ATF/CREG: GAATGACGTCA mutated to AAATGAATT- 
CA; ~53: TGCCTGCC mutated to TGGATCCC) (Clontech). One 
copy of the cyclin A ATFlCREG or ~53 site was cloned in the sense 
orientation upstream the TK promoter [38] in the pTK-LUC reporter 
ulasmid (clone CRElTK-LUC 1251. clone o53.TK-LUC). The PG13- 
LUC reporter plasmid contains ‘the”RGC p53 DNA binding sequence 
linked to a minimal polyoma early promoter [39]. Wild type p53 and 
mutant (A143) expression vectors were as described [40]. 
2.2. Antibody 
Human cyclin A purified from HeLa cells was used to immunize 
mice and raise monoclonal antibodies. Clone 1 lB2 was found to spe- 
cifically recognize human cyclin A in ELISA. It also recognized mouse 
cyclin A. 
2.3. Cell culture, DNA transfection and luciferase assays 
Stable transfections were performed into the mouse cell line NIH- 
3T3. Cells were maintained in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM glu- 
tamine, 100 UI ml-’ of penicillin, and 100 ug ml-’ of streptomycin in 
a humidified atmosphere with 5% COJ95% air. Different constructs 
(pWt-LUC, pdelATF/CREB-LUC, pdelp53-LUC, pTK-LUC, 
pCRElTK-LUC) were cotransfected with the pSV-neo vector (Pro- 
mega) used as a selectable marker into NIH-3T3 cells using the cal- 
cium phosphate precipitation technique [41]. 20 ug of total plasmid 
DNA per 100 mm dish were used. 24 h after transfection, the cells 
were selected for 2 weeks in complete medium with 0.8 mg/ml of G418 
(Geneticin, Gibco-BRL). G418-resistant colonies of the different 
clones were pooled and expanded. These clones were analysed respec- 
tively for luciferase content per cell, which remained constant during a 
2-week observation period. These different populations were synchro- 
nized by serum deprivation (0.2% FCS) for 72 h and then refed with 
10% FCS. We recorded cell cycle stage and cell number by flow 
cytometry (see below) and the luciferase activity was measured by a 
standard assay using a Lumat LB9501 Berthold luminometer. Pro- 
teins were quantified using the BCA assay (Pierce). Results were ex- 
pressed as relative luciferase units per ug total proteins. 
Transient transfections, for ~53 kxpkriments,- were performed into 
Saos-2 cells. maintained as described for NIH-3T3 cells. lo6 cells were 
plated on 60 mm dishes and transfected on the following day by the 
calcium phosphate procedure [41]. The amount of DNA used for 
transfection varied according to the type of analysis performed and 
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is shown in the figure legend. Assays were performed 48 h after 
transfection. 
2.4. Flow cytometry 
lo6 cells were washed twice in PBS and fixed with 75% ethanol in 
PBS for a minimum of 1 h at 4°C. After washing in PBS, cells were 
resuspended in 0.7 ml H,O containing 40 t&ml urouidium iodide and 
50 yg/ml DNase-free RNase A. 20000 event characteristics were ac- 
quired using a FACStar Plus (Becton Dickinson). Cell cycle phases 
were analysed using the Cell Fit program. For measurement of rela- 
tive cell size, ethanol-fixed and/or living cells were analysed by for- 
ward angle light scatter (FSC). 
2.5. Northern blotting 
Total RNA was prepared using standard procedures [42] and ana- 
lysed by Northern blot. The blots were probed with total human 
cyclin A cDNA probe [43]. The probe was labelled with the Multi- 
prime system (Amersham). The same blots were dehybridized and 
probed subsequently with a 28s rRNA oligonucleotide probe to nor- 
malize the amounts of mRNAs loaded [44]. 
2.6. Western blot analysis 
NIH-3T3 cells (3-6X IO6 cells) were washed twice with PBS, lysed 
in 150 ul Laemmli buffer, and boiled for 5 min [45]. 20 ug of protein 
were fractioned on 12.5% SDS-PAGE and then transferred onto 
PVDF membranes (BioRad). Membranes were blocked in Tris-buf- 
fered saline (20 mM Tris-HCl, pH 7.5/137 mM NaCl) containing 5% 
non-fat dry milk. The blots were then probed with a monoclonal 
antibody directed against purified human cyclin A (1: 1000 in blocking 
solution) overnight at 4°C washed in Tris-buffered saline, and then 
incubated with horseradish peroxidase-conjugated goat anti-mouse 
IgG (1:2000) for 1 h at 25°C. Peroxidase activity was visualized by 
the enhanced chemiluminescence (ECL) detection system (Amer- 
sham). 
3. Results 
The most relevant part of the cyclin A promoter is shown in 
Fig. 1. The promoter region contains several DNA sequences 
that are known to participate in the transcriptional control of 
the gene (ATFKREB, E2F, CDE-CHR). In addition, several 
putative recognition sites (~53 and Spl) may participate to the 
cell-cycle dependent transcriptional regulation of the gene. We 
performed site directed mutagenesis in order to evaluate the 
respective roles of p53 and ATFlCREB binding sites in the 
periodic transcription of the cyclin A gene. Each site was 
mutated independently by nucleotide substitution in the cyclin 
A promoter-luciferase construct pWt-LUC, which extends 
from positions -925 to +245 relative to the major transcrip- 
tion start site (Fig. 1). Both wild type and mutant constructs 
were stably transfected into NIH-3T3 cells and luciferase ac- 
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Fig. 1. Map of human cyclin A proximal promoter. A schematic diagram of the human cyclin A promoter indicating the position of consensus 
binding sites for transcription factors: Spl, ATF/CREB, E2F, CDE, CHR and ~53. Diamonds indicate minor transcription start sites (located 
between positions -48 and +l). The major transcription start site is indicated by the arrow (+l). Translation (ATG codon) starts at position 
256. Sequence of the mutant promoter in plasmids pdelATF/CREB-LUC and pdelp53-LUC is also shown, and compared to the wild type se- 
quence (pWt-LUC). 
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tivity was measured after synchronization in GO by serum 
deprivation and re-stimulation by fetal calf serum. Under 
these conditions, cells entered S phase 14 h after stimulation 
and reached G2/M after 22 h (Fig. 2). 
We first monitored the cell cycle regulation of the wild type 
promoter in cells containing pWt-LUC. As shown in Fig. 3, 
the luciferase activity was increased as cells entered S phase. 
This activity precisely reflects the promoter activity, as the 
turn-over of luciferase is rapid in these cells, with a half-life 
of 2 h (data not shown). Luciferase activity increased in par- 
allel with the endogenous cyclin A mRNA in late Gl (10 h 
after serum stimulation) and remained high as cells proceeded 
to G2/M (22 h). In addition, cyclin A protein was not detect- 
able in GO cells and during the first 10 h after stimulation, i.e. 
during most Gl, and dramatically increased at 18 h, when 
most cells had entered S phase. These data demonstrate that 
luciferase activity in these stable cell lines closely mirrors the 
physiological regulation of the cyclin A gene, i.e. a repression 
of the promoter in GO/G1 and a transcriptional activation in 
late Gl followed by a plateau in S and G2. 
We then compared kinetics of expression driven by p53 or 
ATFlCREB mutant cyclin A promoter to that driven by the 
wild type construct. First, we monitored cyclin A promoter 
down-regulation during serum deprivation (Fig. 4A). Lucifer- 
ase activity under control of the wild type cyclin A promoter, 
decreased to basal levels within 72 h. Mutation of either ATF/ 
CREB or p53 sites did not impair this down-regulation. Sec- 
ond, we analysed cyclin A promoter activation after serum 
stimulation. We observed no significant deregulation when 
the ~53 site was mutated. The timing of activation as well 
as the level of luciferase activity produced from the mutant 
Fig. 2. Analysis of NIH-3T3 cell synchronization by flow cytometry 
after propidium iodide staining. Growth-arrested NIH-3T3 cells were 
obtained by serum deprivation (0.2% FCS) for 48 h, and then refed 
with 10% FCS. They were allowed to proceed through one cell cy- 
cle, S phase starting at 14 h. The two peaks represent Gl phase 
cells (2n DNA contents) and G2/M phase cells (4n DNA contents). 
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Fig. 3. Cell cycle regulation of cyclin A in NIH-3T3 cells after ser- 
um stimulation of cells synchronized in GO by serum deprivation. 
(A) Luciferase activity driven by the cyclin A promoter. (B) North- 
ern blot showing cyclin A mRNA accumulation at the indicated 
time after serum stimulation. The blot was then hybridized to a 28s 
oligonucleotide probe for normalization size in kilobases is indicated 
on the right. (C) Western blot showing cyclin A protein accumula- 
tion at the indicated time after serum stimulation. The two bands 
correspond probably to phosphorylated isoforms as described [47]. 
Molecular weight markers are shown on the left (M). 
construct paralleled that of the wild type (Fig. 4B). In con- 
trast, promoter activity was impaired when the ATFlCREB 
binding site was mutated (Fig. 4C). As cells proceeded to S 
and G2 phases, the level of luciferase activity produced from 
the mutant construct increased to a value only 6-7-fold great- 
er than that of GO cells as compared to 19-fold greater in the 
case of the wild type promoter. In a parallel experiment, we 
established two other cell lines containing either zero or one 
copy of the human cyclin A ATFICREB site linked to the 
minimal HSV-TK promoter. Neither construct gave rise to 
the increase of luciferase activity in late Gl and S phases 
that is observed with the Wt-cyclin A promoter construct 
(Fig. 4D). These data demonstrate that the ATF/CREB site 
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Fig. 4. Kinetics of luciferase activity in synchronised NIH-3T3 cells stably transfected with wild type or mutated cyclin A promoter-luciferase 
constructs. First, the activity from the three constructs was monitored during serum deprivation (A). Second, the activity was monitored after 
serum stimulation: (B) pWt-LUC and pdelp53-LUC, (C) pWt-LUC and pdelATF/CREB-LUC, (D) pWt-LUC, pTK-LUC and pCREl.TK- 
LUC. The level of induction for each construct tested correspond to the values relative to activity in GO cells. Results are the mean of three in- 
dependent determinations. 
is involved in the transactivation of the cyclin A gene but is 
not sufficient to confer a cell cycle dependent regulation to an 
heterologous promoter. 
It has been suggested that p53 may repress the cyclin A 
promoter in neuroblastoma cells [28]. In order to identify 
the sequences in the cyclin A promoter that may be respon- 
sible for p53-mediated repression, we first analysed a series of 
5’-deletion constructs (A-F, [20]) in transient transfection as- 
says. Saos-2 cells, which carry a deletion in the p53 gene, were 
cotransfected with the selected cyclin A-promoter luciferase 
constructs and normal/mutant p53 expression vectors. We 
used the Ala143 mutant, which is found in numerous human 
cancers, as a control devoid of transactivating activity [40]. As 
shown in Fig. 5A, wild type p53 repressed the cyclin A pro- 
moter in a dose dependent manner whereas mutant p53 had 
no repressing activity. 5’-terminal deletion to position -79 
(pWt/F-LUC) in the cyclin A promoter reduced the promoter 
activity by 20-fold [20] but did not abolish the repression 
effect of p53 (Fig. 5A). Similar results were found with inter- 
mediate deletion constructs (data not shown). Thus, there is 
no p53 specific element upstream of -79 which is responsible 
for p53-mediated promoter repression. These experiments 
mapped the minimal region sufficient to observe the repres- 
sion effect to -79/+245. In a second series of experiments, we 
investigated the functionality of the putative p53 DNA bind- 
ing element located at position +53 (see Fig. 1). p53 is known 
to activate transcription of target genes through its binding to 
a specific DNA binding element. Mutation of the p53 binding 
site in the cyclin A promoter did not alter the promoter ac- 
tivity (data not shown) or impair p53-mediated repression 
(Fig. 5A). In addition, the human cyclin A p53 site was un- 
able to confer p53 responsiveness to the minimal HSV-TK 
promoter (Fig. 5A) in contrast to the RGC p53 binding se- 
quence (Fig. 5B). In fact, we observed repression of the HSV- 
TK promoter by wild type p53 as previously described for 
other promoters containing a TATA sequence [31-361. All 
1 300 
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z? 0 150 
B 0.4 9 
100 
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PLy Py; p53m TK 
L"C L"C PO13 
Fig. 5. Repression of cyclin A promoter upon p53 expression. Saos- 
2 cells were transfected with 2 pg reporter plasmids (closed bar), or 
together with increasing amounts of Wt p53 expression plasmids 
(0.1, 0.5, 2 kg: dotted bars) or 2 pg of Ala143 mutant p53 expres- 
sion plasmid (open bar). (A) The reporter plasmids are indicated 
(see Fig. 1 and section 2). (B) pG13 reporter plasmid was used to 
monitor the transactivation activity of p53 [39]. Results are ex- 
pressed as fold induction relative to the activity of the reporter plas- 
mid alone (referred to as 1). 
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these data demonstrate that the ~53 site is not implicated in 
the regulation of the cyclin A gene. 
4. Discussion 
The human cyclin A gene is transcribed in a cell-cycle de- 
pendent manner, starting in late Gl and increasing until G2 
phase. The main goal of the present study was to investigate 
whether the ATFKREB and p53 sites located in the promoter 
might be involved in the transcriptional regulation of the 
gene. 
Our experiments demonstrate that the ATFlCREB site is 
necessary for a high level of cyclin A expression from late Gl 
until G2 phase. We have previously shown that transcription 
factors of the CREBKREM family are able to repress and 
transactivate the cyclin A promoter through their binding to 
the ATFKREB site. The finding that the activity of CREB/ 
CREM factors is cell cycle dependent led to the hypothesis 
that they might be involved in cyclin A promoter transactiva- 
tion in late Gl [25]. While our present data indicate that the 
ATFKREB site is not responsible for cell-cycle specific acti- 
vation, we identify this site as a key sequence operating to up- 
regulate the cyclin A promoter at the GUS transition when 
cyclin A protein is required for the entry into S phase. Inter- 
estingly, the same site was recently implicated in cyclin A 
promoter down-regulation in contact-inhibited endothelial 
cells [26] and in Chinese hamster lung fibroblasts upon treat- 
ment with TGF-B [27]. These findings are in contrast to our 
observation that this site is not involved in repression ob- 
served in serum-deprived cells. It is likely, the effects of multi- 
ple pathways converge on the ATFKREB site which thus acts 
as the final target of both positive and negative membrane 
derived signals. 
In a separate set of experiments, we investigated the me- 
chanism underlying the p53-mediated regulation of cyclin A 
gene. Initial experiments had suggested that p53 might repress 
cyclin A expression [28]. ~53 is a transactivating protein that 
is able to activate transcription of genes containing a specific 
~53 DNA binding element. The cyclin A gene contains a 
putative ~53 binding site located in the 5’ untranslated region. 
Our experiments show that this site is unable to mediate trans- 
activation by ~53; in addition careful examination of this 
sequence revealed that the first part of the site has only 7110 
conserved nucleotides and the second part 500 when com- 
pared to the latest concensus ~53 binding sequence [46]. ~53 
is also able to down-regulate transcription of promoters con- 
taining a TATA box element, this was shown for several early 
genes such as C--OS, c-&n and c-myc [29,30]. In the case of the 
cyclin A gene, our results show that repression upon ~53 ex- 
pression occurs with a minimal cyclin A promoter, suggesting 
an interference with the transcription complex. The originality 
of this phenomenon reside in the absence of a TATA sequence 
in the cyclin A promoter. Our results thus extend interference 
by ~53 to a TATA-less promoter. 
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